Physician profile
David W Hudson
NPI 1558390021
$4,414.09
in general payments reported to CMS, 2019-2025
23 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $368 · 2021: $416 · 2022: $492 · 2023: $503 · 2024: $693 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,051.74 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $570.74 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $388.86 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $371.95 | 2020-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $325.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $308.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.19 | 2019-2024 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $206.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $171.22 | 2019-2021 | |
| Novo Nordisk INC | $155.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $153.36 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $84.37 | 2021-2024 | |
| Dexcom, INC. | $78.35 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $49.23 | 2021-2024 | |
| Mylan Specialty L.P. | $38.34 | 2021-2024 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.96 | 2022 | |
| Shield Therapeutics INC | $30.11 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $22.97 | 2024 | Voquezna |
| Itamar Medical INC | $22.76 | 2025 | Watchpatone |
| Sumitomo Pharma America, INC. | $18.97 | 2025 | Gemtesa |
| Shire North American Group INC | $15.06 | 2019 | |
| Exact Sciences Corporation | $13.70 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.